For help on how to get the results you want, see our search tips.
351 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Repatha (updated)
Evolocumab, Dyslipidemias, Hypercholesterolemia
Date of authorisation: 17/07/2015,
, Revision: 11, Authorised, Last updated: 17/10/2019
-
List item
Human medicine European public assessment report (EPAR): Laventair Ellipta (previously Laventair) (updated)
umeclidinium bromide, vilanterol, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 08/05/2014,, Revision: 12, Authorised, Last updated: 17/10/2019
-
List item
Human medicine European public assessment report (EPAR): Anoro Ellipta (previously Anoro) (updated)
umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 08/05/2014,, Revision: 13, Authorised, Last updated: 17/10/2019
-
List item
Human medicine European public assessment report (EPAR): Vosevi (updated)
Sofosbuvir, velpatasvir, voxilaprevi, Hepatitis C, Chronic
Date of authorisation: 26/07/2017,, 
, Revision: 5, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Maviret (updated)
glecaprevir / pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017,, , Revision: 8, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Dectova (updated)
Zanamivir, Influenza, Human
Date of authorisation: 26/04/2019,, Revision: 1, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Spherox (updated)
spheroids of human autologous matrix-associated chondrocytes, Cartilage Diseases
Date of authorisation: 10/07/2017,, Revision: 3, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Kisqali (updated)
ribociclib succinate, Breast Neoplasms
Date of authorisation: 22/08/2017,, Revision: 2, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Halimatoz (updated)
adalimumab, Hidradenitis Suppurativa, Psoriasis, Arthritis, Juvenile Rheumatoid, Uveitis, Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic
Date of authorisation: 26/07/2018,, 
, Revision: 5, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Exviera (updated)
dasabuvir sodium, Hepatitis C, Chronic
Date of authorisation: 14/01/2015,, , Revision: 16, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Vyndaqel (updated)
tafamidis, Amyloidosis
Date of authorisation: 16/11/2011,, 
, 
, Revision: 14, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Uptravi (updated)
Selexipag, Hypertension, Pulmonary
Date of authorisation: 12/05/2016,, Revision: 10, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Orphacol (updated)
cholic acid, Digestive System Diseases, Metabolism, Inborn Errors
Date of authorisation: 12/09/2013,
Date of refusal: 25/05/2012,, , , Revision: 7, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Cabometyx (updated)
cabozantinib s-malate, Carcinoma, Renal Cell
Date of authorisation: 09/09/2016,, , Revision: 5, Authorised, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Lenvima (updated)
lenvatinib mesylate, Thyroid Neoplasms
Date of authorisation: 28/05/2015,, , Revision: 9, Authorised, Last updated: 15/10/2019
-
List item
Human medicine European public assessment report (EPAR): Glivec (updated)
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Gastrointestinal Stromal Tumors, Dermatofibrosarcoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome
Date of authorisation: 07/11/2001,, Revision: 36, Authorised, Last updated: 15/10/2019
-
List item
Human medicine European public assessment report (EPAR): Ofev (updated)
nintedanib, Idiopathic Pulmonary Fibrosis
Date of authorisation: 14/01/2015,, , Revision: 11, Authorised, Last updated: 15/10/2019
-
List item
Human medicine European public assessment report (EPAR): Natpar (updated)
parathyroid hormone, Hypoparathyroidism
Date of authorisation: 24/04/2017,, , 
, Revision: 7, Authorised, Last updated: 14/10/2019
-
List item
Human medicine European public assessment report (EPAR): Symkevi (updated)
tezacaftor, ivacaftor, Cystic Fibrosis
Date of authorisation: 31/10/2018,, , Revision: 2, Authorised, Last updated: 14/10/2019
-
List item
Human medicine European public assessment report (EPAR): Kalydeco (updated)
ivacaftor, Cystic Fibrosis
Date of authorisation: 22/07/2012,, , Revision: 19, Authorised, Last updated: 14/10/2019
-
List item
Human medicine European public assessment report (EPAR): Truxima (updated)
rituximab, Lymphoma, Non-Hodgkin, Arthritis, Rheumatoid, Wegener Granulomatosis, Leukemia, Lymphocytic, Chronic, B-Cell, Microscopic Polyangiitis
Date of authorisation: 17/02/2017,, , Revision: 9, Authorised, Last updated: 11/10/2019
-
List item
Human medicine European public assessment report (EPAR): EndolucinBeta (updated)
lutetium (177 Lu) chloride, Radionuclide Imaging
Date of authorisation: 06/07/2016,, Revision: 5, Authorised, Last updated: 11/10/2019
-
List item
Human medicine European public assessment report (EPAR): Symtuza (updated)
darunavir, cobicistat, emtricitabine, tenofovir alafenamide, HIV Infections
Date of authorisation: 21/09/2017,, Revision: 7, Authorised, Last updated: 11/10/2019
-
List item
Human medicine European public assessment report (EPAR): Zerbaxa (updated)
ceftolozane sulfate, tazobactam sodium, Bacterial Infections
Date of authorisation: 18/09/2015,, Revision: 9, Authorised, Last updated: 11/10/2019
-
List item
Human medicine European public assessment report (EPAR): Xermelo (updated)
telotristat etiprate, Carcinoid Tumor, Neuroendocrine Tumors
Date of authorisation: 17/09/2017,, , Revision: 6, Authorised, Last updated: 11/10/2019